{"id":33876,"date":"2021-08-25T08:48:56","date_gmt":"2021-08-25T08:48:56","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=77821"},"modified":"2021-08-25T08:48:56","modified_gmt":"2021-08-25T08:48:56","slug":"genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2","status":"publish","type":"post","link":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/","title":{"rendered":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021"},"content":{"rendered":"
\n
\n
\n

L’entreprise affiche une croissance explosive de l’activit\u00e9 d’organisation de d\u00e9veloppement et de fabrication sous contrat (CDMO) de th\u00e9rapie g\u00e9nique et cellulaire (GCT) et des investissements strat\u00e9giques en th\u00e9rapie g\u00e9nique et cellulaire<\/p>\n

NANJING, Chine, 25 ao\u00fbt\u00a02021 \/PRNewswire\/ — GenScript Biotech Corporation (HKEX: 1548.HK<\/a>) (GenScript) a publi\u00e9 aujourd’hui ses r\u00e9sultats financiers du premier semestre 2021 pour le semestre clos le 30\u00a0juin. Le Groupe a \u00e9galement annonc\u00e9 avoir \u00e9tendu sa pr\u00e9sence dans l’industrie de la th\u00e9rapie g\u00e9nique et cellulaire gr\u00e2ce \u00e0 des investissements massifs.<\/p>\n

Au cours du premier semestre 2021, le Groupe a maintenu une forte dynamique dans tous les secteurs d’activit\u00e9. Le chiffre d’affaires total a augment\u00e9 de 38 % pour atteindre 229,6\u00a0millions de dollars et la marge brute a augment\u00e9 de 28,1 % pour atteindre 138,6\u00a0millions de dollars.<\/p>\n

Le chiffre d’affaires de l’activit\u00e9 de th\u00e9rapie non cellulaire du Groupe a augment\u00e9 de 36,6 % pour atteindre 195,7 millions de dollars, avec un b\u00e9n\u00e9fice brut de 104,7 millions de dollars, soit une augmentation de 23,0 % en glissement annuel, y compris la perc\u00e9e historique de son activit\u00e9 de d\u00e9veloppement et de fabrication sous contrat de th\u00e9rapies g\u00e9niques et cellulaires dans la croissance explosive du chiffre d’affaires. Ce r\u00e9sultat s’appuie sur les premiers investissements du Groupe dans ce domaine et sur ses avantages en mati\u00e8re de solutions de R&D et de fabrication de plasmides et lentivirus. En ce qui concerne l’activit\u00e9 de th\u00e9rapie cellulaire du Groupe, le chiffre d’affaires a augment\u00e9 de 46,8\u00a0% sur un an pour atteindre 33,9\u00a0millions de dollars, gr\u00e2ce \u00e0 la reconnaissance continue de ses succ\u00e8s et \u00e0 des investissements importants.<\/p>\n

En tant que fournisseur de synth\u00e8se g\u00e9nique num\u00e9ro un dans le monde, GenScript a \u00e9tabli une base technique solide pour ses activit\u00e9s de th\u00e9rapie g\u00e9nique et cellulaire. Tandis que les activit\u00e9s de GenScript dans le domaine des services et des produits des sciences de la vie, le d\u00e9veloppement de contrats biologiques et l’organisation de la fabrication, et les activit\u00e9s de th\u00e9rapie cellulaire sont toutes en train d’atteindre une forte dynamique, le Groupe \u00e9tend sa pr\u00e9sence \u00e0 travers la cha\u00eene de valeur de la th\u00e9rapie g\u00e9nique et cellulaire en investissement de fa\u00e7on intensive.<\/p>\n

Au cours du premier semestre 2021, les d\u00e9penses de R&D ont augment\u00e9 de 51,6\u00a0% en glissement annuel pour atteindre 175,1\u00a0millions de dollars. L’entreprise de th\u00e9rapie non cellulaire a investi environ 10\u00a0% de son chiffre d’affaires dans la construction d’installations de bonnes pratiques de fabrication et dans d’autres extensions d’infrastructures. L’activit\u00e9 de th\u00e9rapie cellulaire a d\u00e9pens\u00e9 154,5 millions de dollars en R&D, une augmentation de 52,1 % par rapport \u00e0 l’ann\u00e9e pr\u00e9c\u00e9dente, avec une concentration des investissements sur les \u00e9tudes cliniques de cilta-cel et les installations de fabrication qui soutiennent les essais cliniques en cours et la commercialisation future de l’entreprise.<\/p>\n

GenScript est en train d’inaugurer l’essor de la th\u00e9rapie g\u00e9nique et cellulaire comme la prochaine r\u00e9volution de l’industrie bio-technologique, en exploitant l’\u00e9norme potentiel des organisations de recherche contractuelle et des plateformes de d\u00e9veloppement et de fabrication contractuelles. Au cours des deux \u00e0 trois prochaines ann\u00e9es, l’entreprise de sciences de la vie et l’entreprise de d\u00e9veloppement et de fabrication de produits biologiques augmenteront leurs investissements strat\u00e9giques dans ce domaine. Cela comprend des investissements dans les services li\u00e9s \u00e0 la th\u00e9rapie g\u00e9nique et cellulaire, l’utilisation de la technologie d’automatisation pour moderniser les lignes de production, et l’acc\u00e9l\u00e9ration du lancement des produits de th\u00e9rapie cellulaire en cours et de la R&D dans les nouveaux pipelines.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

L\u2019entreprise affiche une croissance explosive de l\u2019activit\u00e9 d\u2019organisation de d\u00e9veloppement et de fabrication sous contrat (CDMO) de th\u00e9rapie g\u00e9nique et cellulaire (GCT) et des investissements strat\u00e9giques en th\u00e9rapie g\u00e9nique et cellulaire NANJING, Chine, 25 ao\u00fbt\u00a02021 \/PRNewswire\/ \u2014 GenScript Biotech Corporation (HKEX: 1548.HK) (GenScript) a publi\u00e9 aujourd\u2019hui ses r\u00e9sultats financiers du premier semestre 2021 pour le [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[261],"tags":[165,166],"yoast_head":"\nGenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice\" \/>\n<meta property=\"og:description\" content=\"L\u2019entreprise affiche une croissance explosive de l\u2019activit\u00e9 d\u2019organisation de d\u00e9veloppement et de fabrication sous contrat (CDMO) de th\u00e9rapie g\u00e9nique et cellulaire (GCT) et des investissements strat\u00e9giques en th\u00e9rapie g\u00e9nique et cellulaire NANJING, Chine, 25 ao\u00fbt\u00a02021 \/PRNewswire\/ \u2014 GenScript Biotech Corporation (HKEX: 1548.HK) (GenScript) a publi\u00e9 aujourd\u2019hui ses r\u00e9sultats financiers du premier semestre 2021 pour le [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\" \/>\n<meta property=\"og:site_name\" content=\"South Africa Voice\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-25T08:48:56+00:00\" \/>\n<meta name=\"author\" content=\"South Africa Voice\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"South Africa Voice\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\"},\"author\":{\"name\":\"South Africa Voice\",\"@id\":\"https:\/\/southafricavoice.com\/#\/schema\/person\/128917b3a36684d2cce00774bab91964\"},\"headline\":\"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021\",\"datePublished\":\"2021-08-25T08:48:56+00:00\",\"dateModified\":\"2021-08-25T08:48:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\"},\"wordCount\":645,\"publisher\":{\"@id\":\"https:\/\/southafricavoice.com\/#organization\"},\"keywords\":[\"Africa\",\"South Africa\"],\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\",\"url\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\",\"name\":\"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice\",\"isPartOf\":{\"@id\":\"https:\/\/southafricavoice.com\/#website\"},\"datePublished\":\"2021-08-25T08:48:56+00:00\",\"dateModified\":\"2021-08-25T08:48:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/southafricavoice.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/southafricavoice.com\/#website\",\"url\":\"https:\/\/southafricavoice.com\/\",\"name\":\"South Africa Voice\",\"description\":\"The Ultimate Voice of People of Africa\",\"publisher\":{\"@id\":\"https:\/\/southafricavoice.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/southafricavoice.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/southafricavoice.com\/#organization\",\"name\":\"South Africa Voice\",\"url\":\"https:\/\/southafricavoice.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/southafricavoice.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/southafricavoice.com\/wp-content\/uploads\/2020\/06\/cropped-sav_logo-op.png\",\"contentUrl\":\"https:\/\/southafricavoice.com\/wp-content\/uploads\/2020\/06\/cropped-sav_logo-op.png\",\"width\":164,\"height\":80,\"caption\":\"South Africa Voice\"},\"image\":{\"@id\":\"https:\/\/southafricavoice.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/southafricavoice.com\/#\/schema\/person\/128917b3a36684d2cce00774bab91964\",\"name\":\"South Africa Voice\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/southafricavoice.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"South Africa Voice\"},\"url\":\"https:\/\/southafricavoice.com\/author\/southafricavoice01\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/","og_locale":"en_US","og_type":"article","og_title":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice","og_description":"L\u2019entreprise affiche une croissance explosive de l\u2019activit\u00e9 d\u2019organisation de d\u00e9veloppement et de fabrication sous contrat (CDMO) de th\u00e9rapie g\u00e9nique et cellulaire (GCT) et des investissements strat\u00e9giques en th\u00e9rapie g\u00e9nique et cellulaire NANJING, Chine, 25 ao\u00fbt\u00a02021 \/PRNewswire\/ \u2014 GenScript Biotech Corporation (HKEX: 1548.HK) (GenScript) a publi\u00e9 aujourd\u2019hui ses r\u00e9sultats financiers du premier semestre 2021 pour le [\u2026]","og_url":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/","og_site_name":"South Africa Voice","article_published_time":"2021-08-25T08:48:56+00:00","author":"South Africa Voice","twitter_card":"summary_large_image","twitter_misc":{"Written by":"South Africa Voice","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#article","isPartOf":{"@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/"},"author":{"name":"South Africa Voice","@id":"https:\/\/southafricavoice.com\/#\/schema\/person\/128917b3a36684d2cce00774bab91964"},"headline":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021","datePublished":"2021-08-25T08:48:56+00:00","dateModified":"2021-08-25T08:48:56+00:00","mainEntityOfPage":{"@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/"},"wordCount":645,"publisher":{"@id":"https:\/\/southafricavoice.com\/#organization"},"keywords":["Africa","South Africa"],"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/","url":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/","name":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021 - South Africa Voice","isPartOf":{"@id":"https:\/\/southafricavoice.com\/#website"},"datePublished":"2021-08-25T08:48:56+00:00","dateModified":"2021-08-25T08:48:56+00:00","breadcrumb":{"@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/southafricavoice.com\/genscript-biotech-annonce-ses-resultats-du-premier-semestre-2021-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/southafricavoice.com\/"},{"@type":"ListItem","position":2,"name":"GenScript Biotech annonce ses r\u00e9sultats du premier semestre 2021"}]},{"@type":"WebSite","@id":"https:\/\/southafricavoice.com\/#website","url":"https:\/\/southafricavoice.com\/","name":"South Africa Voice","description":"The Ultimate Voice of People of Africa","publisher":{"@id":"https:\/\/southafricavoice.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/southafricavoice.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/southafricavoice.com\/#organization","name":"South Africa Voice","url":"https:\/\/southafricavoice.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southafricavoice.com\/#\/schema\/logo\/image\/","url":"https:\/\/southafricavoice.com\/wp-content\/uploads\/2020\/06\/cropped-sav_logo-op.png","contentUrl":"https:\/\/southafricavoice.com\/wp-content\/uploads\/2020\/06\/cropped-sav_logo-op.png","width":164,"height":80,"caption":"South Africa Voice"},"image":{"@id":"https:\/\/southafricavoice.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/southafricavoice.com\/#\/schema\/person\/128917b3a36684d2cce00774bab91964","name":"South Africa Voice","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southafricavoice.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"South Africa Voice"},"url":"https:\/\/southafricavoice.com\/author\/southafricavoice01\/"}]}},"_links":{"self":[{"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/posts\/33876"}],"collection":[{"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/comments?post=33876"}],"version-history":[{"count":0,"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/posts\/33876\/revisions"}],"wp:attachment":[{"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/media?parent=33876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/categories?post=33876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/southafricavoice.com\/wp-json\/wp\/v2\/tags?post=33876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}